0RRB.LSE DocMorris AG
- Market cap
- GBP 60.8M
- P/E
- -
- P/B
- -
- ROE
- -59.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0RRB.LSE undervalued?
Graham numberThe Graham number of DocMorris AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DocMorris AG fundamental analysis
No fundamental analysis for DocMorris AG yet.
DocMorris AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DocMorris AG
DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally. The company offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional health care services to doctors, pharmacies, insurers, and health institutions. It sells its products to online mail-ord…
Full company profileDocMorris AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DocMorris AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 880M | 983M | 1.21B | 1.36B | 1.48B | 1.73B | 931M | 969M | 1.02B | 1.12B | 2.40B |
| Gross Profit | 63.1M | 56.7M | 79.0M | 60.6M | 60.4M | 61.8M | 6.85M | 203M | 71.1M | 106M | 220M |
| Operating Income | -2.54M | -35.1M | -34.2M | -83.5M | -131M | -198M | -139M | 89.7M | -91.5M | -84.3M | -164M |
| EBITDA | -409K | -23.6M | -18.1M | -13.7M | -76.1M | -151M | -110M | -54.6M | -37.0M | -39.4M | -80.1M |
| Net Income | -12.8M | -36.2M | -39.0M | -52.4M | -136M | -226M | -170M | 82.3M | -97.3M | -134M | -212M |
| EPS | -1.86 | -6.58 | -6.14 | -6.04 | -15 | -23 | -16 | 7.05 | -8.25 | -2.60 | -4.34 |
| Balance Sheet | |||||||||||
| Total Assets | 262M | 462M | 727M | 992M | 1.28B | 1.27B | 1.10B | 866M | 778M | 825M | 776M |
| Total Liabilities | 158M | 168M | 283M | 586M | 747M | 784M | 749M | 436M | 438M | 416M | 418M |
| Shareholders' Equity | 104M | 294M | 444M | 406M | 532M | 485M | 351M | 431M | 340M | 409M | 358M |
| Cash & Short-term Investments | 25.4M | 108M | 231M | 205M | 301M | 278M | 156M | 104M | 95.4M | 150M | 89.8M |
| Total Debt | 59.1M | 4.14M | 117M | 356M | 526M | 525M | 529M | 331M | 312M | 289M | 266M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -13.8M | -22.2M | -33.2M | -82.6M | -67.5M | -131M | -97.3M | -87.4M | -26.5M | -88.3M | -82.5M |
| Capital Expenditure | 19.9M | 21.6M | 31.5M | 41.5M | 59.8M | 63.5M | 46.6M | 4.99M | 1.36M | 1.77M | 1.76M |
| Free Cash Flow | -33.8M | -43.9M | -64.7M | -124M | -127M | -194M | -144M | -92.4M | -27.8M | -90.0M | -84.3M |
| Ratios | |||||||||||
| ROE | -12.3% | -12.3% | -8.8% | -12.9% | -25.5% | -46.6% | -48.5% | 19.1% | -28.6% | -32.9% | -59.3% |
| ROA | -4.9% | -7.8% | -5.4% | -5.3% | -10.6% | -17.8% | -15.5% | 9.5% | -12.5% | -16.3% | -27.4% |
| Net Profit Margin | -1.5% | -3.7% | -3.2% | -3.9% | -9.2% | -13.1% | -18.3% | 8.5% | -9.6% | -12.0% | -8.9% |
| Debt to Equity | 0.57x | 0.01x | 0.26x | 0.88x | 0.99x | 1.08x | 1.51x | 0.77x | 0.92x | 0.71x | 0.74x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DocMorris AG dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | GBP 180M | 19 | - |
| 2020 | GBP 363M | 40 | - |
| 2019 | GBP 205M | 24 | - |
| 2018 | GBP 183M | 29 | - |
| 2017 | GBP 166M | 30 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 593:292 on May 13, 2025.
Who owns DocMorris AG
- Insiders 35.95%
- Institutions 23.05%
- Public & others 41.00%
- Shares outstanding 6.19M
- Free float 35.9M
DocMorris AG company profile
- Company name
- DocMorris AG
- Ticker
- 0RRB.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 1,097
- Fiscal year end
- December
- Address
- WalzmUehlestrasse 49, Frauenfeld, Switzerland, 8500
- Phone
- 41 52 724 00 20
- Website
- corporate.docmorris.com/en
About DocMorris AG
DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally. The company offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional health care services to doctors, pharmacies, insurers, and health institutions. It sells its products to online mail-order pharmacies, and private individuals under the DocMorris, PromoFarma by DocMorris, and TeleClinic brands. The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.
DocMorris AG management
9- Mr. Walter OberhansliFounder & Chairman · born 1958
- Mr. Walter HessCEO & Member of Executive Board · born 1965
- Mr. Daniel WüestCFO & Member of Executive Board · born 1970
- Mr. David MasoChief AI Health Officer & Member of Executive Board · born 1971
- Mr. Kaspar NiklausCOO & Member of Executive Board · born 1968
- Mr. Pablo Ros GomezCTO & Member of Executive Board · born 1982
- Ms. Andrea SkersiesChief Commercial Officer & Member of the Executive Board · born 1972
- Dr. Daniel GrigatGroup Head of Investor Relations & Sustainability
- Torben BonnkeDirector of Communications